Table 2.
Tumor Characteristics and Treatment Completion by According to CCRT Response
| Characteristic | CR (n=221) | PR (n=104) | SD (n=50) | PD (n=118) | p-value* |
|---|---|---|---|---|---|
| Shape of tumor | <0.001 | ||||
| Protruding | 86 (39.8) | 32 (32.0) | 21 (41.0) | 32 (28.6) | |
| Ulcerative | 40 (18.5) | 14 (14.0) | 11 (22.0) | 19 (17.0) | |
| Combined | 66 (30.6) | 53 (53.0) | 18 (36.0) | 58 (51.8) | |
| Superficial | 24 (11.1) | 1 (1.0) | 0 | 3 (2.7) | |
| Lumen involvement | 0.001 | ||||
| Partial | 164 (74.9) | 64 (61.5) | 21 (42.0) | 64 (56.1) | |
| Circumferential | 55 (25.1) | 40 (38.4) | 29 (58.0) | 50 (43.9) | |
| Location | 0.14 | ||||
| Cervical | 9 (4.1) | 1 (1.0) | 1 (2.0) | 3 (2.6) | |
| Upper thorax | 32 (14.5) | 23 (22.1) | 4 (8.0) | 21 (18.3) | |
| Mid thorax | 103 (46.6) | 38 (36.5) | 25 (50.0) | 59 (51.3) | |
| Lower thorax | 77 (34.8) | 42 (40.4) | 20 (40.0) | 32 (27.8) | |
| Length, cm | 4.1±2.0 | 5.0±2.2 | 5.1±2.8 | 5.4±2.3 | 0.05 |
| Clinical stage | <0.001 | ||||
| I | 49 (22.3) | 4 (3.9) | 3 (6.09) | 5 (4.3) | |
| II | 93 (42.3) | 28 (27.2) | 11 (22.0) | 16 (13.8) | |
| III | 52 (23.6) | 37 (36.9) | 17 (35.3) | 41 (35.3) | |
| IV | 26 (11.8) | 34 (33.0) | 19 (38.0) | 54 (46.6) | |
| Radiation dose, Gy | 58.6±5.3 | 58.9±5.0 | 51.4±15.3 | 57.6±9.3 | 0.001† |
| Chemotherapy cycle | 3.7±1.7 | 3.8±1.8 | 2.5±1.5 | 3.5±1.9 | 0.001† |
| Incomplete CCRT | 32 (14.3) | 41 (38.7) | 40 (78.3) | 56 (47.5) | 0.001 |
| Cause of incomplete CCRT | <0.001 | ||||
| Complication/poor medical condition | 31 (96.7) | 31 (75.6) | 27 (67.5) | 35 (62.5) | |
| Unresponsive (PD) | 0 | 0 | 0 | 17 (30.4) | |
| Death/refuse | 1 (3.3) | 10 (24.4) | 13 (32.5) | 4 (7.1) | |
| Chemotherapy regimen | 0.19 | ||||
| FP | 191 (86.4) | 94 (90.4) | 40 (80.0) | 98 (83.8) | 0.217 |
| XP | 24 (10.9) | 7 (6.7) | 10 (20.0) | 15 (12.7) | |
| Others | 6 (2.7) | 3 (2.9) | 0 | 5 (4.2) | |
Data are presented as number (%) or mean±SD. Missing data are present.
CCRT, concurrent chemoradiotherapy; CR, complete remission; PR, partial remission; SD, stationary disease; PD, progressive disease; FP, 5-fluorouracil and cisplatin; XP, capecitabine and cisplatin.
*
p-values were derived from analysis of variance or chi-square test; †p-values were derived from t-test comparing CR and SD.